1801 — Innovent Biologics Share News
0.000.00%
Last trade - 00:00- HK$150.85bn
- HK$130.09bn
- CNY13.04bn
-BUZZ-China's Innovent Biologics hits all-time high on H1 growth
China, HK stocks track global tech rebound; gold miners rally
China's Innovent Biologics hits all-time high on higher H1 results
China's Innovent Biologics H1 revenue, profit rise on strong product sales
Brief: Innovent Announces 2026 Interim Results And Business Updates
Focus: Snoring, subways and stealth ads: how big pharma targets China's waistline
Chinese vaccine makers jump on news of key success in cancer treatment
Chinese vaccine makers jump on news of key success in cancer treatment, CanSino leads
Innovent Biologics jumps most in 3 weeks on robust product revenue growth
Brief: Innovent Biologics Says First Half 2026 Product Revenue Exceeds RMB8.2 Billion
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
Factbox: Race to launch weight-loss pills heats up as smaller players advance
Eli Lilly transfers commercialization rights for breast cancer drug in China (updated)
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug
Pfizer, Innovent GLP-1 drugs clear China insurance hurdle (updated)
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Pentagon casts dark cloud over China biotech
Innovent climbs most in a week on new drug application for gastric cancer
Brief: Innovent Biologics Says NMPA Accepts NDA For IBI343 (Arcotatug Tavatecan)